Lano, 122 patient HCQ late treatment study: 33% lower mortality [p=0.28] and 39% lower combined mortality/ICU admission [p=0.23] https://c19p.org/lano
copied to clipboard
Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort
et al., Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199
33% lower mortality with HCQ+AZ, p=0.28. Retrospective 122 French dialysis patients.69% lower combined mortality/ICU, p=0.11, for the subgroup not requiring O2 on diagnosis (slightly earlier treatment).
|
risk of death, 33.1% lower, RR 0.67, p = 0.28, treatment 56, control 66, adjusted per study, odds ratio converted to relative risk.
|
|
risk of death/ICU, 38.9% lower, RR 0.61, p = 0.23, treatment 17 of 56 (30.4%), control 28 of 66 (42.4%), NNT 8.3, adjusted per study, odds ratio converted to relative risk.
|
|
risk of death/ICU, 68.7% lower, RR 0.31, p = 0.11, treatment 4 of 36 (11.1%), control 11 of 31 (35.5%), NNT 4.1, not requiring O2 on diagnosis (relatively early treatment).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lano et al., 10/21/2020, retrospective, France, Europe, peer-reviewed, median age 73.5, 30 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.